"10.1371_journal.pone.0140782","plos one","2015-10-16T00:00:00Z","José Manuel Molina-Guijarro; Carolina García; Álvaro Macías; Luis Francisco García-Fernández; Cristina Moreno; Fernando Reyes; Juan Fernando Martínez-Leal; Rogelio Fernández; Valentín Martínez; Carmen Valenzuela; M Pilar Lillo; Carlos M Galmarini","Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain; Departamento de Química Física Biológica, Instituto de Química-Física Rocasolano (CSIC), Madrid, Spain; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Madrid, Spain; Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain","Conceived and designed the experiments: JMMG LFGF FR CV MPL CMG. Performed the experiments: JMMG CG AM CM RF VM MPL. Analyzed the data: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Contributed reagents/materials/analysis tools: JMMG CG AM LFGF CM FR JFML RF VM CV MPL CMG. Wrote the paper: JMMG CV MPL CMG.","The authors of this manuscript have read the journals policy and have the following competing interests: José Manuel Molina-Guijarro, Luis Francisco García-Fernández, Juan Fernando Martínez-Leal, Rogelio Fernández, Valentín Martínez, and Carlos M. Galmarini are employees and shareholders of PharmaMar S.A. Actual patent application of elisidepsin belongs to PharmaMar SA. There are no products in development or marketed products to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","10","José Manuel Molina-Guijarro","JMMG",12,TRUE,6,7,12,4,TRUE,TRUE,TRUE,1,"3",FALSE
